Skip to main content

CORRECTION article

Front. Neurol., 08 August 2023
Sec. Multiple Sclerosis and Neuroimmunology
Volume 14 - 2023 | https://doi.org/10.3389/fneur.2023.1245622

Corrigendum: Adaptive and innate immune responses in multiple sclerosis with anti-CD20 therapy: gene expression and protein profiles

This article is a correction to:

  1. Adaptive and innate immune responses in multiple sclerosis with anti-CD20 therapy: Gene expression and protein profiles

    1. Read original article
\r\nChloe C. Fong&#x;Chloe C. Fong†Julian Spencer&#x;Julian Spencer†Quentin Howlett-PrietoQuentin Howlett-PrietoXuan Feng Xuan Feng*Anthony T. Reder Anthony T. Reder*
  • Department of Neurology, University of Chicago Medicine, Chicago, IL, United States

A corrigendum on
Adaptive and innate immune responses in multiple sclerosis with anti-CD20 therapy: gene expression and protein profiles

by Fong, C. C., Spencer, J., Howlett-Prieto, Q., Feng, X., and Reder, A. T. (2023). Front. Neurol. 14:1158487. doi: 10.3389/fneur.2023.1158487

In the published article, there was an error. The level of CD79B RNA at 2 weeks was typed incorrectly in the text.

A correction has been made to Results, “Expression of B-cell-related genes relevant to MS is downregulated after ocrelizumab infusion,” paragraph 1. This sentence previously stated:

“Genes included CD79A (fold-change at 2 weeks vs. time 0 = −272; at 6 months vs. time 0 = −172; not shown in figure because of extreme scale of change) and CD79B (−2.47; and – 2.46) (Figure 4A).”

The corrected sentence appears below:

“Genes included CD79A (fold-change at 2 weeks vs. time 0 = −272; at 6 months vs. time 0 = −172; not shown in figure because of extreme scale of change) and CD79B (−55.0; and – 2.46) (Figure 4A).”

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Keywords: anti-CD20 therapy, B cell, multiple sclerosis, ocrelizumab, T cell, TLR

Citation: Fong CC, Spencer J, Howlett-Prieto Q, Feng X and Reder AT (2023) Corrigendum: Adaptive and innate immune responses in multiple sclerosis with anti-CD20 therapy: gene expression and protein profiles. Front. Neurol. 14:1245622. doi: 10.3389/fneur.2023.1245622

Received: 23 June 2023; Accepted: 27 June 2023;
Published: 08 August 2023.

Edited and reviewed by: Francesco Patti, University of Catania, Italy

Copyright © 2023 Fong, Spencer, Howlett-Prieto, Feng and Reder. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Xuan Feng, xfeng@neurology.bsd.uchicago.edu; Anthony T. Reder, areder@neurology.bsd.uchicago.edu

†These authors have contributed equally to this work and share first authorship

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.